JP7499259B2 - αケトグルタル酸カルシウムを製造するためのプロセス - Google Patents

αケトグルタル酸カルシウムを製造するためのプロセス Download PDF

Info

Publication number
JP7499259B2
JP7499259B2 JP2021540377A JP2021540377A JP7499259B2 JP 7499259 B2 JP7499259 B2 JP 7499259B2 JP 2021540377 A JP2021540377 A JP 2021540377A JP 2021540377 A JP2021540377 A JP 2021540377A JP 7499259 B2 JP7499259 B2 JP 7499259B2
Authority
JP
Japan
Prior art keywords
alpha
water
ketoglutaric acid
mixture
calcium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021540377A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022502489A5 (cg-RX-API-DMAC7.html
JP2022502489A (ja
Inventor
ユージーン ペレイラ,デイビッド
デオ,ケシャフ
Original Assignee
ポンス デ レオン ヘルス デジグネイテッド アクティビティ カンパニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ポンス デ レオン ヘルス デジグネイテッド アクティビティ カンパニー filed Critical ポンス デ レオン ヘルス デジグネイテッド アクティビティ カンパニー
Publication of JP2022502489A publication Critical patent/JP2022502489A/ja
Publication of JP2022502489A5 publication Critical patent/JP2022502489A5/ja
Application granted granted Critical
Publication of JP7499259B2 publication Critical patent/JP7499259B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/41—Preparation of salts of carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/41—Preparation of salts of carboxylic acids
    • C07C51/412—Preparation of salts of carboxylic acids by conversion of the acids, their salts, esters or anhydrides with the same carboxylic acid part
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/41—Preparation of salts of carboxylic acids
    • C07C51/418—Preparation of metal complexes containing carboxylic acid moieties
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/347—Saturated compounds containing more than one carboxyl group containing keto groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Fodder In General (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2021540377A 2018-09-25 2019-09-23 αケトグルタル酸カルシウムを製造するためのプロセス Active JP7499259B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862736320P 2018-09-25 2018-09-25
US62/736,320 2018-09-25
PCT/US2019/052498 WO2020068705A1 (en) 2018-09-25 2019-09-23 Process of making calcium alpha-ketoglutarate

Publications (3)

Publication Number Publication Date
JP2022502489A JP2022502489A (ja) 2022-01-11
JP2022502489A5 JP2022502489A5 (cg-RX-API-DMAC7.html) 2022-10-04
JP7499259B2 true JP7499259B2 (ja) 2024-06-13

Family

ID=69952136

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021540377A Active JP7499259B2 (ja) 2018-09-25 2019-09-23 αケトグルタル酸カルシウムを製造するためのプロセス

Country Status (18)

Country Link
US (1) US11802103B2 (cg-RX-API-DMAC7.html)
EP (1) EP3856166A4 (cg-RX-API-DMAC7.html)
JP (1) JP7499259B2 (cg-RX-API-DMAC7.html)
KR (1) KR102833111B1 (cg-RX-API-DMAC7.html)
CN (1) CN112955139B (cg-RX-API-DMAC7.html)
AU (1) AU2019350699B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021005668A2 (cg-RX-API-DMAC7.html)
CA (1) CA3112205A1 (cg-RX-API-DMAC7.html)
CL (1) CL2021000728A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021004529A2 (cg-RX-API-DMAC7.html)
IL (1) IL281761B2 (cg-RX-API-DMAC7.html)
MX (1) MX2021003482A (cg-RX-API-DMAC7.html)
MY (1) MY203278A (cg-RX-API-DMAC7.html)
PE (1) PE20211816A1 (cg-RX-API-DMAC7.html)
PH (1) PH12021550403A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202102204PA (cg-RX-API-DMAC7.html)
TW (1) TWI863930B (cg-RX-API-DMAC7.html)
WO (1) WO2020068705A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112955139B (zh) 2018-09-25 2025-04-18 庞塞迪利昂健康特定活动公司 用于制备α-酮戊二酸钙的方法
CN112941116B (zh) * 2021-01-04 2022-12-02 上海朴颐化学科技有限公司 一种酶法制备α-酮戊二酸钙的方法
CN114105761B (zh) * 2021-11-19 2024-06-21 广东派特埃尔生物科技有限公司 一种α-酮戊二酸钠盐的合成工艺
CN115974679A (zh) * 2022-12-20 2023-04-18 绍兴市精益生物化工有限公司 α-酮戊二酸钙盐制备方法
CN119977789A (zh) * 2025-02-12 2025-05-13 江苏惠利生物科技有限公司 一种离子交换树脂制备高纯度α-酮戊二酸钙的方法

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007536288A (ja) 2004-05-06 2007-12-13 オステオロジックス エイ/エス 有機金属塩類を製造するための高収率で迅速な合成法
JP2008502679A (ja) 2004-06-17 2008-01-31 エスゲーペー アンド ソンズ アクティエボラーグ α−ケトグルタル酸及び関連化合物の血漿中脂質を低下させるための使用
JP2010095516A (ja) 2008-09-22 2010-04-30 Nippon Synthetic Chem Ind Co Ltd:The α−オキソカルボン酸の金属塩の製造方法
CN102976927A (zh) 2012-12-26 2013-03-20 天津天成制药有限公司 α-酮戊二酸钙的制备方法
JP2014055273A (ja) 2012-09-14 2014-03-27 National Institute Of Agrobiological Sciences シュウ酸カルシウムを含む氷核活性剤
PL231635B1 (pl) 2017-01-03 2019-03-29 Politechnika Poznanska Sposób produkcji kwasu alfa-ketoglutarowego (AKG) z jednoskładnikowych roztworów wodnych

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2776926A (en) 1955-08-04 1957-01-08 Eugene S Sharpe Preparation of alpha-ketoglutaric acid by serratia marcescens
US2917528A (en) 1956-08-24 1959-12-15 Victor Chemical Works Alkanolaminealkanephosphonic acids and salts thereof
US2841616A (en) * 1956-10-30 1958-07-01 Campbell Soup Co Process for the recovery of alpha-ketoglutaric acid
US3875304A (en) 1970-04-24 1975-04-01 Schlitz Brewing Co J Livestock feed composition and method of preparing the same
US4045585A (en) 1976-05-19 1977-08-30 Decel Corporation Flavored animal food compositions
DE3151196A1 (de) * 1981-12-23 1983-06-30 Kurt Heinz Prof. Dr. 7800 Freiburg Bauer Verfahren zur herstellung von gut loeslichen 5-aminosalicylsaeure-arzneimittelzubereitungen
US6451341B1 (en) 1990-02-05 2002-09-17 Thomas J. Slaga Time release formulation of vitamins, minerals and other beneficial supplements
US5646187A (en) 1992-05-20 1997-07-08 Ab Erik Vinnars Use of alpha-ketoglutarate
US6306430B1 (en) 1998-04-16 2001-10-23 The Iams Company Process for decreasing adiposity using vitamin a as a dietary supplement
US6905707B2 (en) 1998-05-28 2005-06-14 Medical Research Institute Controlled release arginine alpha ketoglutarate
CO5140079A1 (es) 1998-10-14 2002-03-22 Novartis Ag Composicion farmaceutica de liberacion sostenida y metodo para liberar un agente farmaceuticamente activo de liberacion sostenida y metodo para liberar un agente far- maceuticamente activo
US6649654B1 (en) 1999-11-23 2003-11-18 The Regents Of The University Of California Methods for identifying and using IKK inhibitors
US7169755B2 (en) 2000-12-20 2007-01-30 Alcon, Inc. Solution for removing cataracts via liquefracture
US20060216358A1 (en) * 2003-05-07 2006-09-28 Christian Hansen Controlled release composition containing a strontium salt
US20090005437A1 (en) 2004-08-09 2009-01-01 Eyal Gottlieb Alpha-Ketoglutarates and Their Use as Therapeutic Agents
ES2510690T3 (es) 2004-12-17 2014-10-21 Alan B. Cash Método para extender la esperanza de vida y retrasar la aparición de enfermedad relacionada con la edad
US20060234250A1 (en) 2005-04-15 2006-10-19 Powers Ralph W Iii Methods of screening and compositions for life span modulators
WO2007001883A2 (en) 2005-06-20 2007-01-04 Accera, Inc. Method to reduce oxidative damage and improve mitochondrial efficiency
US20070105942A1 (en) 2005-11-08 2007-05-10 Heuer Marvin A Supplemental dietary composition for turning on anabolic switches in muscle, stimulating and/or optimizing protein synthesis, and/or potently signaling muscle building and/or growth via molecular pathways
US8367121B2 (en) 2005-11-23 2013-02-05 Florida A & M University Nutraceutical agent for attenuating the neurodegenerative process associated with Parkinson's disease
PL379512A1 (pl) 2006-04-21 2007-10-29 Sgp & Sons Ab Nowe metody i ich zastosowanie
PL226695B1 (pl) 2006-07-03 2017-08-31 Danuta Kruszewska Środek do zastosowania w zapobieganiu i/lub hamowaniu kolonizacji Helicobacter pylori, zastosowanie soli kwasu alfa‑ketoglutarowego z metalami alkalicznymi i ziem alkalicznych do wytwarzania środka leczniczego oraz dodatku do żywności do zapobiegania i/lub hamowania kolonizacji Helicobacter pylori
JP2010522190A (ja) 2007-03-19 2010-07-01 メタプロテオミクス, エルエルシー 骨及び関節の健康を助成するための方法と組成物
US20110039935A1 (en) 2007-07-02 2011-02-17 Entress Ab Use of pharmacologically active chemical compounds
EP2033623A1 (en) 2007-09-07 2009-03-11 Cutech S.R.L. Compositions comprising ornithine ketoglutarate (OKG)
CN101759553A (zh) 2008-11-21 2010-06-30 扬子江药业集团北京海燕药业有限公司 α-酮酸钙的制备方法
DE102009016119A1 (de) 2009-04-03 2010-10-14 Evonik Degussa Gmbh Nahrungsergänzungsmittel enthaltend alpha-Ketosäuren zur Unterstützung der Diabetestherapie
WO2010118419A2 (en) 2009-04-10 2010-10-14 Haiyan Qi Novel anti-aging agents and methods to identify them
CN102481269B (zh) 2009-05-11 2015-10-07 博格有限责任公司 包含辅酶q10的药物组合物及其制备方法
EP3120709A1 (en) 2009-05-28 2017-01-25 IAMS Europe B.V. Pet food in the form of a coated kibble
US9950019B2 (en) 2009-06-12 2018-04-24 Generex Pharmaceuticals, Inc. Compositions and methods for the prevention and treatment of brain diseases and conditions
PL2448577T3 (pl) 2009-06-30 2017-02-28 Derman Biomedicine Co. Ltd. Kompozycje zawierające berberynę lub jej analogi do leczenia trądziku różowatego lub chorób skóry związanych z zaczerwienieniem twarzy
WO2011060305A1 (en) 2009-11-12 2011-05-19 Nox Technologies, Inc. Potato skin compositions that lower cytosolic nadh level to mimic calorie restriction
WO2012114204A2 (en) 2011-02-15 2012-08-30 Ecole Polytechnique Federale De Lausanne (Epfl) Epfl-Tto Methods of treating mitochondrial dysfunction
JP2014512372A (ja) 2011-04-18 2014-05-22 ネステク ソシエテ アノニム α−HICA及びエイコサペンタエン酸を含有する栄養組成物
WO2012174537A2 (en) 2011-06-16 2012-12-20 President And Fellows Of Harvard College Small molecule screening for mouse satellite cell proliferation
CN102586347B (zh) * 2012-03-06 2014-04-09 江南大学 一种两阶段pH控制高产a-酮戊二酸的方法
US9532997B2 (en) 2012-04-03 2017-01-03 Whitehead Institute For Biomedical Research Compositions and methods for promoting intestinal stem cell function
ITBO20120226A1 (it) 2012-04-24 2013-10-25 Alfa Wassermann Spa Composizioni comprendenti ornitina alfa-chetoglutarato, processi per il loro ottenimento e il loro uso.
PL3398594T3 (pl) 2012-09-19 2024-11-04 Grespo Ab Kompozycje do ulepszenia funkcji mózgu
CA2896646A1 (en) 2012-12-27 2014-07-03 Hayashibara Co., Ltd. Skin-exterior anti-ageing composition and production method therefor
WO2014116985A1 (en) 2013-01-25 2014-07-31 Winning The Fight Inc. Composition for treatment of neurodegenerative disease
US9511057B2 (en) 2013-03-15 2016-12-06 The Board Of Trustees Of The Leland Stanford Junior University Methods for treating denervation-induced muscle atrophy
BR112015024186B1 (pt) 2013-03-19 2023-05-09 University Of South Florida Composições e métodos para produção de cetose de elevação e manutenção
US20160263092A1 (en) 2013-12-19 2016-09-15 Twi Biotechnology, Inc. Therapeutic uses of berberine formulations
CN113082009A (zh) 2014-02-12 2021-07-09 加利福尼亚大学董事会 用于治疗衰老和与年龄相关的疾病和症状的组合物和方法
WO2015171723A1 (en) 2014-05-06 2015-11-12 Research Development Foundation Methods for treating insulin resistance and for sensitizing patients to glp1 agonist therapy
KR102596106B1 (ko) 2014-06-30 2023-10-30 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 연령-관련 증상 및 질환의 치료를 위한 케토부티레이트 화합물 및 조성물
KR20250008786A (ko) 2014-07-29 2025-01-15 센젠 하이타이드 바이오파마슈티컬 리미티드 베르베린 염, 우르소데옥시콜산 염 및 병용물, 이들의 제조 및 응용 방법
WO2016019224A1 (en) 2014-07-31 2016-02-04 Indiana University Research And Technology Corporation Antithetical regulation of endothelial ace and ace2 by brg1-foxm1 complex underlies pathological cardiac hypertrophy
CN104529755B (zh) * 2014-12-29 2016-01-06 精晶药业股份有限公司 一种从转化液中分离α-酮戊二酸的方法
US20180050048A1 (en) 2015-04-06 2018-02-22 SHENZHEN HJGHTIDE-BIOPHARMAGEUTiCAL, LTD. Conjugate compounds of ursodeoxycholic, berberine or l-carnitine, and compositions and methods thereof
CN107849083A (zh) 2015-06-10 2018-03-27 益力舒健康公司 用于治疗皮肤病症的烟酰胺核苷和紫檀芪组合物和方法
WO2017008060A1 (en) 2015-07-08 2017-01-12 Unity Biotechnology, Inc. Compositions and methods for treating senescence-associated diseases and disorders
CN109803647A (zh) 2016-09-30 2019-05-24 加州大学董事会 α-丁酮酸、α-酮戊二酸和2-羟基丁酸用于刺激毛发生长
MX2017004010A (es) 2017-03-27 2018-02-09 Antonio Hernandez Miramontes Jorge Mezcla de oxalacetato, alfacetoglutarato, ácido tartánico y sales de lactato de calcio y sodio, para tratar pacientes con insuficiencia renal crónica.
CA3061381A1 (en) 2017-04-25 2018-11-01 Buck Institute For Research On Aging COMPOSITIONS COMPRISING α-KETOGLUTARATE FOR EXTENDING LIFESPAN AND HEALTHSPAN
WO2019038655A1 (en) 2017-08-21 2019-02-28 The Regents Of The University Of California COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES
CN112955139B (zh) 2018-09-25 2025-04-18 庞塞迪利昂健康特定活动公司 用于制备α-酮戊二酸钙的方法
US20210369750A1 (en) 2018-10-24 2021-12-02 Ponce De Leon Health Designated Activity Company Nicotinamide riboside compositions for healthspan extension
CN114126599A (zh) 2019-06-10 2022-03-01 巴克老龄化研究所 改变衰老相关分泌表型的方法和组合物
TWI869410B (zh) * 2019-06-10 2025-01-11 愛爾蘭商龐賽德萊昂健康公司 α-酮戊二酸鹽之持續釋放組合物
EP4175978A4 (en) 2020-07-02 2024-06-26 Ponce de Leon Health Designated Activity Company COMPOSITIONS AND METHODS FOR TREATING CRP-MEDIATED DISEASES
CN112941116B (zh) * 2021-01-04 2022-12-02 上海朴颐化学科技有限公司 一种酶法制备α-酮戊二酸钙的方法
CN115974679A (zh) * 2022-12-20 2023-04-18 绍兴市精益生物化工有限公司 α-酮戊二酸钙盐制备方法

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007536288A (ja) 2004-05-06 2007-12-13 オステオロジックス エイ/エス 有機金属塩類を製造するための高収率で迅速な合成法
JP2008502679A (ja) 2004-06-17 2008-01-31 エスゲーペー アンド ソンズ アクティエボラーグ α−ケトグルタル酸及び関連化合物の血漿中脂質を低下させるための使用
JP2010095516A (ja) 2008-09-22 2010-04-30 Nippon Synthetic Chem Ind Co Ltd:The α−オキソカルボン酸の金属塩の製造方法
JP2014055273A (ja) 2012-09-14 2014-03-27 National Institute Of Agrobiological Sciences シュウ酸カルシウムを含む氷核活性剤
CN102976927A (zh) 2012-12-26 2013-03-20 天津天成制药有限公司 α-酮戊二酸钙的制备方法
PL231635B1 (pl) 2017-01-03 2019-03-29 Politechnika Poznanska Sposób produkcji kwasu alfa-ketoglutarowego (AKG) z jednoskładnikowych roztworów wodnych

Also Published As

Publication number Publication date
BR112021005668A2 (pt) 2021-06-22
PE20211816A1 (es) 2021-09-14
EP3856166A1 (en) 2021-08-04
MY203278A (en) 2024-06-21
JP2022502489A (ja) 2022-01-11
MX2021003482A (es) 2021-06-18
EP3856166A4 (en) 2022-06-22
KR20210065120A (ko) 2021-06-03
CO2021004529A2 (es) 2021-04-30
US11802103B2 (en) 2023-10-31
KR102833111B1 (ko) 2025-07-10
IL281761B1 (en) 2025-05-01
TW202024013A (zh) 2020-07-01
AU2019350699B2 (en) 2024-05-23
CN112955139B (zh) 2025-04-18
US20210371368A1 (en) 2021-12-02
IL281761B2 (en) 2025-09-01
SG11202102204PA (en) 2021-04-29
PH12021550403A1 (en) 2021-10-04
CL2021000728A1 (es) 2021-10-22
IL281761A (en) 2021-05-31
TWI863930B (zh) 2024-12-01
CA3112205A1 (en) 2020-04-02
WO2020068705A1 (en) 2020-04-02
CN112955139A (zh) 2021-06-11
AU2019350699A1 (en) 2021-04-08

Similar Documents

Publication Publication Date Title
TWI863930B (zh) 用於製備α-酮戊二酸鈣之方法
WO2012039474A1 (ja) ピロロキノリンキノンのカルシウム塩
JP2016516693A (ja) トレプロスチニルの塩
CN109678715A (zh) 2-(1-酰氧正戊基)苯甲酸与碱性氨基酸或氨基胍形成的盐、其制备方法及用途
US3585214A (en) Hydroxyl derivatives of coumarine and processes for the preparation thereof
CN110776519A (zh) 一种硫酸氢氯吡格雷晶型ii的制备方法
US6861525B2 (en) Process for the preparation imidazo[1,2-A]pyridine-3-acetamides
HK40053335B (en) Process of making calcium alpha-ketoglutarate
HK40053335A (en) Process of making calcium alpha-ketoglutarate
JP2005529146A (ja) 中枢神経系障害の治療で使用するための実質的に純粋な固形型3−インドリルピルビン酸のエノール互変異性体
PL157527B1 (pl) Sposób wytwarzania prawoskretnego kwasu 3-/pirydylo-3/-1H,3H-pirolo [1,2-c]tiazolokarboksylowego-730) Pierwszenstwo:02.07.1987,FR,8709376 PL PL PL
US2773872A (en) Dihydroorotic acid
JPS6014026B2 (ja) パンテテイン−s−スルホン酸及びその塩の製造法
WO2024235167A1 (zh) 一种吡唑并吡嗪类化合物及其晶型的制备方法
JPH03145492A (ja) ピロロキノリンキノンエステル
JPH04338330A (ja) チロシン硫酸塩からなる血小板凝集阻止剤
HU179780B (en) Process for preparing thiazolidine-carboxylic acid derivatives
KR910003184B1 (ko) 프롤린 유도체의 제조방법
JPS5852995B2 (ja) フルフラ−ル誘導体の製造法
JPH0560824B2 (cg-RX-API-DMAC7.html)
JPS62298547A (ja) 2−シクロペンテノン誘導体の製造法
JPS6127970A (ja) 5−アルキリデンヒダントイン類の製造法
CZ278017B6 (en) Process for preparing crotonbetaine hydrochloride
JPH03170486A (ja) 新規なオキサゾピロロキノリン化合物
JPS5913499B2 (ja) 2−置換−5−アミノ吉草酸類

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220926

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220926

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230809

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230905

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231204

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240305

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240507

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240603